Amgen presents positive results from talimogene laherparepvec Phase 3 study in patients with metastatic melanoma
1 June 2013 | By Amgen
Amgen announced detailed results from a pivotal Phase 3 trial...
List view / Grid view
1 June 2013 | By Amgen
Amgen announced detailed results from a pivotal Phase 3 trial...
29 May 2013 | By Amgen
Innovative joint venture to address unmet medical needs of patients in Japan...
9 May 2013 | By Amgen
Goal is to bring Amgen's Vectibix® (panitumumab) to chinese patients...
7 May 2013 | By Amgen
Study meets primary endpoint of non-inferiority in monotherapy setting...
22 April 2013 | By Amgen
Amgen welcomes a new report from the European Commission...
8 April 2013 | By Amgen
Amgen supports the direction WHO is taking...
19 March 2013 | By Amgen
These are the first Phase 3 results of this novel approach to cancer therapy...
8 February 2013 | By Amgen
Four inspirational individuals making a positive impact for those affected by Cancer...
7 February 2013 | By Amgen
Amgen outlined the company's long-term strategy during a Business Review meeting with analysts and investors in New York City...
26 January 2013 | By Amgen
Results from Pegfilgrastim and Anti-VEGF Evaluation Study...
25 January 2013 | By Amgen
"Amgen endorses state policies that would put patients first..."
16 January 2013 | By Amgen
Amgen announced top-line results of the Phase 3 Aranesp® RED-HF® Trial...
16 January 2013 | By Amgen
Amgen announced plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore...
13 December 2012 | By Amgen
Amgen announced the appointment of Robert A. Eckert to its Board of Directors...
13 December 2012 | By Amgen
Amgen announced appointments to its Board of Directors...